Etretinate for retinoid-responsive dermatoses: further observations of long-term therapy

In a retrospective study of 70 patients the frequency of side-effects associated with long-term low-dose etretinate were investigated. Etretinate, a vitamin A analogue, is sometimes required as chronic therapy in severe papulosquamous disease. The patients had received etretinate for up to 11 years with cumulative doses of 11.6–98.9 g. Mucocutaneous toxicity as well as hyperlipidaemia were generally dose related in severity. New skeletal and extra-skeletal calcification were noted in 16% of patients. These patients had a cumulative dose of at least 25 g etretinate. Side-effects associated with long-term low-dose etretinate were generally well tolerated. It is suggested that monitoring for skeletal and extraskeletal abnormalities be considered as the cumulative dose approaches 25 g.

[1]  W. Helsel,et al.  Isotretinoin and the axial skeleton , 1992, The Lancet.

[2]  M. Stacey,et al.  Rapid interphase FISH diagnosis of trisomy 18 on blood smears , 1992, The Lancet.

[3]  P. Taylor,et al.  Skeletal hyperostosis in patients receiving chronic, very-low-dose isotretinoin. , 1992, Archives of dermatology.

[4]  J. Saurat,et al.  Risk:benefit ratio in the treatment of psoriasis with systemic retinoids , 1990, The British journal of dermatology.

[5]  P. Tfelt-Hansen,et al.  SPINAL CORD COMPRESSION AFTER LONG-TERM ETRETINATE , 1989, The Lancet.

[6]  L. Halkier‐Sørensen,et al.  A retrospective study of bone changes in adults treated with etretinate. , 1989, Journal of the American Academy of Dermatology.

[7]  R. K. Landow.  Etretinate. A clinician's view. , 1988, Dermatologic clinics.

[8]  E. Hodak,et al.  Adverse Effects of Retinoids , 1988, Medical toxicology and adverse drug experience.

[9]  G. Goerz,et al.  ABNORMAL RETINAL FUNCTION ASSOCIATED WITH LONG-TERM ETRETINATE? , 1988, The Lancet.

[10]  John J. Voorhees,et al.  Continuing medical education (Therapy) , 1987 .

[11]  S. Glück,et al.  Retrospective radiographic study of skeletal changes after long‐term etretinate therapy , 1987, The British journal of dermatology.

[12]  J. Mcguire,et al.  Skeletal changes associated with chronic isotretinoin and etretinate administration. , 1987, Dermatologica.

[13]  A. Shalita.  Mucocutaneous and systemic toxicity of retinoids: monitoring and management. , 1987, Dermatologica.

[14]  N. Lowe,et al.  Etretin therapy for severe psoriasis. Evaluation of initial clinical responses. , 1987, Archives of dermatology.

[15]  L. Gerber,et al.  Extraspinal tendon and ligament calcification associated with long-term therapy with etretinate. , 1986, The New England journal of medicine.

[16]  J. Voorhees,et al.  Lack of skeletal radiographic changes during short-term etretinate therapy for psoriasis. , 1986, Dermatologica.

[17]  N. Lowe,et al.  Etretinate therapy for psoriasis: clinical responses, remission times, epidermal DNA and polyamine responses. , 1983, Journal of the American Academy of Dermatology.

[18]  F. K. Jacobsen,et al.  Side effects due to RO 10-9359 (Tigason). A retrospective study. , 1982, Dermatologica.

[19]  H. Roenigk,et al.  A study of potential hepatotoxicity of etretinate used in the treatment of psoriasis. , 1982, Journal of the American Academy of Dermatology.

[20]  T. Nigra,et al.  General clinical toxicology of oral retinoids. , 1982, Journal of the American Academy of Dermatology.